Epstein Secrets

ve and quantitative information about investment processes ■ Regular meetings with investors ■ Investments by partners and employees comprise 7% of Och-Ziff's AUMI ■ Och-Ziff's partners receive a substantial majority of their compensation from distributions tied to profitability As of September I. 2015 u

dit Donald Young—MD, Senior Portfolio Manager,ICS - U.S. Ad eel Shafiqullah—MD, Senior Portfolio Manager, ICS - Europe Mathieu Clavel —MD, Head of European Corporate Credit Taj Sidhu—MD, Head of European Private Investments Brett Klein Executive Managing Director Portfolio Management Global Corporate Credit Research

Mount Sinai Medical Center. Harold Kelly is Head of Global Convertible and Derivative Arbitrage and Risk Management for Och-Ziff and is a member of Och-Ziff's Partner Management Committee. Mr. Kelly is also an Executive Managing Director. Prior to joining Och-Ziff in 1995, Mr. Kelly spent seven years tradi

r. Shafiqullah holds a B.S. in Business Administration from the University of Southern California. Mathieu Clavel is a Managing Director and Head of European Corporate Credit for Och-Ziff. Prior to joining Och-Ziff in 2009, Mr. Clavel was a Senior Analyst at Silverpoint Capital. Before that, he worked as a Vice President

Mount Sinai Medical Center. Harold Kelly is Head of Global Convertible and Derivative Arbitrage and Risk Management for Och-Ziff and is a member of Och-Ziff's Partner Management Committee. Mr. Kelly is also an Executive Managing Director. Prior to joining Och-Ziff in 1995, Mr. Kelly spent seven years tradi

r. Shafiqullah holds a B.S. in Business Administration from the University of Southern California. Mathieu Clavel is a Managing Director and Head of European Corporate Credit for Och-Ziff. Prior to joining Och-Ziff in 2009, Mr. Clavel was a Senior Analyst at Silverpoint Capital. Before that, he worked as a Vice President